Buprenorphine

"Buprenorphine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.

Descriptor ID	D002047
MeSH Number(s)	D03.132.577.249.150 D03.605.497.150 D03.633.400.686.150 D04.615.723.795.150
Concept/Terms	Buprenorphine Buprenorphine Buprenex Buprenex Prefin Prefin Subutex Subutex Buprex Temgesic Temgésic 6029-M 6029-M 6029 M 6029M RX-6029-M RX 6029 M RX6029M Buprenorphine Hydrochloride Buprenorphine Hydrochloride Hydrochloride, Buprenorphine

Below are MeSH descriptors whose meaning is more general than "Buprenorphine".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Alkaloids [D03.132]
Opiate Alkaloids [D03.132.577]
Morphinans [D03.132.577.249]
Buprenorphine [D03.132.577.249.150]
Heterocyclic Compounds, Bridged-Ring [D03.605]
Morphinans [D03.605.497]
Buprenorphine [D03.605.497.150]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 4 or More Rings [D03.633.400]
Morphinans [D03.633.400.686]
Buprenorphine [D03.633.400.686.150]
Polycyclic Compounds [D04]
Polycyclic Aromatic Hydrocarbons [D04.615]
Phenanthrenes [D04.615.723]
Morphinans [D04.615.723.795]
Buprenorphine [D04.615.723.795.150]

Below are MeSH descriptors whose meaning is related to "Buprenorphine".

Below are MeSH descriptors whose meaning is more specific than "Buprenorphine".

Buprenorphine
Buprenorphine, Naloxone Drug Combination

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Buprenorphine" by people in this website by year, and whether "Buprenorphine" was a major or minor topic of these publications.

Bar chart showing 120 publications over 19 distinct years, with a maximum of 21 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2005	1	0	1
2007	1	0	1
2009	3	0	3
2010	1	0	1
2011	3	0	3
2012	3	2	5
2013	4	0	4
2014	1	3	4
2015	4	0	4
2016	1	2	3
2017	2	2	4
2018	4	3	7
2019	5	3	8
2020	5	4	9
2021	12	0	12
2022	21	0	21
2023	12	0	12
2024	10	4	14
2025	2	2	4

Below are the most recent publications written about "Buprenorphine" by people in Profiles.

Morenz AM, Nance RM, Mixson LS, Feinberg J, Smith G, Korthuis PT, Pho MT, Jenkins WD, Friedmann PD, Stopka TJ, Fanucchi LC, Miller WC, Go VF, Westergaard R, Seal DW, Zule WA, Crane HM, Delaney JA, Tsui JI. Barriers to accessing medications for opioid use disorder among rural individuals. Int J Drug Policy. 2025 Jun; 140:104805.

View in: PubMed
Flanagan Balawajder E, Ducharme L, Taylor BG, Lamuda PA, Kolak M, Friedmann PD, Pollack HA, Schneider JA. Barriers to Universal Availability of Medications for Opioid Use Disorder in US Jails. JAMA Netw Open. 2025 Apr 01; 8(4):e255340.

View in: PubMed
Williams BE, Martin SA, Hoffman KA, Andrus MD, Dellabough-Gormley E, Buchheit BM. "It's within your own power": shared decision-making to support transitions to buprenorphine. Addict Sci Clin Pract. 2025 Mar 07; 20(1):22.

View in: PubMed
Lynn T, Kelleher ME, Georges HM, McCauley EM, Logan RW, Yonkers KA, Abrahams VM. Buprenorphine induces human fetal membrane sterile inflammation. J Reprod Immunol. 2025 Mar; 168:104445.

View in: PubMed
Andraka-Christou B, Viglione J, Ahmed F, Del Pozo B, Atkins DN, Clark MH, Totaram R, Pivovarova E. Factors affecting problem-solving court team decisions about medications for opioid use disorder. J Subst Use Addict Treat. 2025 Jan; 168:209525.

View in: PubMed
Chatterjee A, Stewart EA, Assoumou SA, Chrysanthopoulou SA, Zwick H, Harris RA, O'Dea R, Schackman BR, White LF, Linas BP. Health and Economic Outcomes of Offering Buprenorphine in Homeless Shelters in Massachusetts. JAMA Netw Open. 2024 Oct 01; 7(10):e2437233.

View in: PubMed
Stopka TJ, Rottapel R, Friedmann PD, Pivovarova E, Evans EA. Perceptions of extended-release buprenorphine among people who received medication for opioid use disorder in jail: a qualitative study. Addict Sci Clin Pract. 2024 Sep 12; 19(1):68.

View in: PubMed
Chan B, Cook R, Levander X, Wiest K, Hoffman K, Pertl K, Petluri R, McCarty D, Korthuis PT, Martin SA. Buprenorphine discontinuation in telehealth-only treatment for opioid use disorder: A longitudinal cohort analysis. J Subst Use Addict Treat. 2024 Dec; 167:209511.

View in: PubMed
Flanagan Balawajder E, Ducharme L, Taylor BG, Lamuda PA, Kolak M, Friedmann PD, Pollack HA, Schneider JA. Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails. JAMA Netw Open. 2024 Sep 03; 7(9):e2434704.

View in: PubMed
Grande LA, Hutch T, Jack K, Mironov W, Iwuoha J, Muy-Rivera M, Grillo J, Martin SA, Herring A. Ketamine-assisted buprenorphine initiation: a pilot case series. Addict Sci Clin Pract. 2024 Aug 29; 19(1):60.

View in: PubMed

People

Explore

Similar Concepts

Top Journals